Literature DB >> 22361418

Supply chain problems for Chagas disease treatment.

Jennifer Manne1, Callae S Snively, Michael Z Levy, Michael R Reich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22361418     DOI： 10.1016/S1473-3099(12)70001-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.

Authors:  Mario Javier Olivera; Zulma M Cucunubá; Carlos Arturo Álvarez; Rubén Santiago Nicholls
Journal:  Am J Trop Med Hyg       Date:  2015-09-21       Impact factor: 2.345

2.  Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.

Authors:  Colin J Forsyth; Salvador Hernandez; Wilman Olmedo; Adieb Abuhamidah; Mahmoud I Traina; Daniel R Sanchez; Jonathan Soverow; Sheba K Meymandi
Journal:  Clin Infect Dis       Date:  2016-07-17       Impact factor: 9.079

3.  [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America].

Authors:  Gabriela Costa Chaves; Mariana Abi-Saab Arrieche; Joelle Rode; Daniel Mechali; Priscileyne Ouverney Reis; Renato Vieira Alves; Eric Stobbaerts; Nora Girón Aguilar; Isabela Ribeiro
Journal:  Rev Panam Salud Publica       Date:  2017-06-08

4.  Barriers to treatment access for Chagas disease in Mexico.

Authors:  Jennifer M Manne; Callae S Snively; Janine M Ramsey; Marco Ocampo Salgado; Till Bärnighausen; Michael R Reich
Journal:  PLoS Negl Trop Dis       Date:  2013-10-17

5.  Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment.

Authors:  Zulma M Cucunubá; Pierre Nouvellet; Jennifer K Peterson; Sarah M Bartsch; Bruce Y Lee; Andrew P Dobson; Maria-Gloria Basáñez
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.